Versor Investments LP Increases Stake in CVS Health Corporation $CVS

Versor Investments LP boosted its stake in CVS Health Corporation (NYSE:CVS) by 168.4% during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 54,493 shares of the pharmacy operator’s stock after purchasing an additional 34,193 shares during the period. CVS Health comprises 0.7% of Versor Investments LP’s investment portfolio, making the stock its 12th largest position. Versor Investments LP’s holdings in CVS Health were worth $3,759,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other large investors have also recently made changes to their positions in the company. Avion Wealth grew its position in shares of CVS Health by 99.0% in the 2nd quarter. Avion Wealth now owns 380 shares of the pharmacy operator’s stock worth $26,000 after buying an additional 189 shares during the last quarter. Harbor Asset Planning Inc. bought a new stake in shares of CVS Health in the 2nd quarter worth approximately $30,000. Bell Investment Advisors Inc grew its position in shares of CVS Health by 119.8% in the 1st quarter. Bell Investment Advisors Inc now owns 455 shares of the pharmacy operator’s stock worth $31,000 after buying an additional 248 shares during the last quarter. Roxbury Financial LLC grew its position in shares of CVS Health by 78.3% in the 2nd quarter. Roxbury Financial LLC now owns 460 shares of the pharmacy operator’s stock worth $32,000 after buying an additional 202 shares during the last quarter. Finally, ORG Partners LLC grew its position in shares of CVS Health by 418.9% in the 2nd quarter. ORG Partners LLC now owns 467 shares of the pharmacy operator’s stock worth $32,000 after buying an additional 377 shares during the last quarter. 80.66% of the stock is currently owned by institutional investors.

CVS Health Price Performance

Shares of CVS stock opened at $78.13 on Friday. The stock has a market cap of $99.18 billion, a price-to-earnings ratio of 205.61, a PEG ratio of 0.87 and a beta of 0.60. The business’s fifty day moving average is $76.49 and its 200 day moving average is $69.04. CVS Health Corporation has a twelve month low of $43.56 and a twelve month high of $85.15. The company has a quick ratio of 0.62, a current ratio of 0.83 and a debt-to-equity ratio of 0.83.

CVS Health (NYSE:CVS) last released its earnings results on Wednesday, October 29th. The pharmacy operator reported $1.60 EPS for the quarter, topping the consensus estimate of $1.36 by $0.24. CVS Health had a return on equity of 11.45% and a net margin of 0.12%.The business had revenue of $102.87 billion for the quarter, compared to the consensus estimate of $98.85 billion. During the same period in the previous year, the company posted $1.09 earnings per share. The company’s revenue for the quarter was up 7.8% compared to the same quarter last year. CVS Health has set its FY 2025 guidance at 6.550-6.650 EPS. Research analysts expect that CVS Health Corporation will post 5.89 EPS for the current fiscal year.

CVS Health Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Monday, November 3rd. Shareholders of record on Thursday, October 23rd will be issued a $0.665 dividend. This represents a $2.66 annualized dividend and a yield of 3.4%. The ex-dividend date of this dividend is Thursday, October 23rd. CVS Health’s payout ratio is 700.00%.

Insider Buying and Selling

In other CVS Health news, Director Anne A. Finucane sold 7,500 shares of the business’s stock in a transaction on Wednesday, August 20th. The stock was sold at an average price of $71.02, for a total value of $532,650.00. Following the sale, the director directly owned 22,156 shares of the company’s stock, valued at approximately $1,573,519.12. The trade was a 25.29% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Company insiders own 1.22% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently weighed in on CVS shares. The Goldman Sachs Group started coverage on CVS Health in a research report on Tuesday, October 14th. They issued a “buy” rating and a $91.00 price objective on the stock. Cowen reiterated a “buy” rating on shares of CVS Health in a research report on Monday, August 4th. Wall Street Zen lowered CVS Health from a “buy” rating to a “hold” rating in a research report on Saturday. Royal Bank Of Canada upped their price target on CVS Health from $81.00 to $93.00 and gave the stock an “outperform” rating in a research note on Thursday. Finally, Jefferies Financial Group upped their price target on CVS Health from $80.00 to $92.00 in a research note on Wednesday, October 15th. Two investment analysts have rated the stock with a Strong Buy rating, twenty have assigned a Buy rating and four have issued a Hold rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $87.64.

CVS Health Profile

CVS Health Corporation provides health solutions in the United States. It operates through Health Care Benefits, Health Services, and Pharmacy & Consumer Wellness segments. The Health Care Benefits segment offers traditional, voluntary, and consumer-directed health insurance products and related services.